CAS: 32780-64-6; Labetalol Hydrochloride

上下游产品

CAS号22374-89-6 1-甲基-3-苯基丙胺 | CAS号76143-20-9 5-甲酰基-2-羟基苯甲酰胺

2-Hydroxy-5-Benzamide Hydrochloride置于platinum On Activated Charcoal,Palladium Oxide On Charcoal 氢气体系中,用 乙醇 用作溶剂,以67%的收率获得柳胺苄心定
参考文献:来自水杨酰胺的芳基乙醇胺具有α-和β-肾上腺素受体阻断活性.拉贝洛尔,其对映异构体和相关水杨酰胺的制备.
标题:来自水杨酰胺的芳基乙醇胺具有α-和β-肾上腺素受体阻断活性.拉贝洛尔,其对映异构体和相关水杨酰胺的制备.
摘要:已经制备了一系列基于水杨酰胺的苯乙醇胺(3),并显示出具有β-肾上腺素阻断特性.当碱性氮原子被某些芳烷基取代时,这些化合物也会封闭α-肾上腺素受体.1-甲基-3-苯基丙基衍生物拉贝洛尔(34)在动物和人类中均具有降压作用,并描述了其四种立体异构体的合成.在两个不对称中心具有r构型的对映体90具有大部分的β-阻断活性,但是几乎没有α-阻断活性.在醇碳上具有s构型并且在氨基取代基上具有r构型的化合物主要是α-肾上腺素受体阻断剂89.
Doi:10.1021/jm00348A013

专利信息

专利号:US-6030613-A
优先权日:1995-01-17
标题:Receptor specific transepithelial transport of therapeutics
发明人：BLUMBERG RICHARD S; SIMISTER NEIL E; LENCER WAYNE I
权利人:BRIGHAM & WOMENS HOSPITAL; UNIV BRANDEIS
摘要:The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

专利号:US-7547436-B2
优先权日:1995-01-17
标 题:Receptor specific transepithelial transport of therapeutics
发明人：BLUMBERG RICHARD S; LENCER WAYNE I; SIMISTER NEIL E
权利人:BRIGHAM & WOMENS HOSPITAL; UNIV BRANDEIS
摘要:The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

专利号:US-2014315720-A1
优先权日:2012-10-24
标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
发明人：FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
权利人:CELANESE ACETATE LLC
摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

专利号:CN-209631424-U
优先权日:2018-11-22
标 题 :A kind of labetalol hydrochloride Material synthesis centrifuge